Addressing Challenges to Optimal Diagnosis and Treatment of Invasive Fungal Infections

Release Date :
February 16, 2018
Expiration Date :
February 16, 2019

John R. Perfect, MD
James B. Duke Professor of Medicine
Chief, Division of Infectious Diseases and International Health
Duke University Medical Center
Durham, North Carolina

PROGRAM OVERVIEW

Fungal infections are rampant throughout the world, causing an estimated one billion skin infections, more than 100 million mucosal infections, and approximately one million deaths per year. For most people, fungal infections are relatively minor, but some fungal infections are life-threatening. Those at greatest risk for life-threatening invasive fungal infections (IFIs) are people with weakened immune systems. As medicine advances, more people are being subjected to immunosuppression than ever before, causing an increase in IFIs. The overall prevalence of IFIs is 8.2% in high-risk patients who are affected by hematological malignancies or solid tumors and patients with solid organ or hematopoietic transplants, acquired immunodeficiency syndrome, and other diagnoses.

Hospital Medicine Summit (HMS) is an innovative, multi-topic educational initiative designed specifically for hospital-based healthcare providers (hospitalists, internal medicine physicians, physician assistants, nurse practitioners, pharmacists, and nurses). With significant changes occurring in the healthcare system, there is an increased demand on hospital-based healthcare providers to provide care that impacts patients not only in the acute setting, but as they transition back into the community and are managed in the chronic-care healthcare system.

TARGET AUDIENCE

This educational initiative has been designed for hospital-based healthcare providers, including physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Identify challenges in the diagnosis of common IFIs and recognize clinical circumstances that require empirical treatment
  • Review the emerging patterns and underlying mechanisms of fungal resistance
  • Describe current guideline recommendations for the treatment of IFIs
TARGET AUDIENCE

There are no fees for participating and receiving CME credit for this activity. During the period of February 16, 2018 through February 16, 2019, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number: 0530-9999-17-346-H01-P)

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or hms@integrityce.com.
For information about ACPE or ANCC accreditation of this activity, please contact Postgraduate Institute for Medicine at (303) 799-1930 or inquires@pimed.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education and Global Education Group are committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

John R. Perfect, MD
Consultant: Astellas Pharma US, Inc., Cidara Therapeutics, Matinas BioPharma, Scynexic, Viamet Pharmaceuticals, Inc., Vical
Research: Amplyx Pharmaceuticals, Inc., Pfizer, Viamet Pharmaceuticals, Inc.

The following planners and managers, Andrea Funk, Lindsay Borvansy, Liddy Knight, Ashley Marostica, RN, MSN, and Patima Tanapat, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education, Global Education Group, and Astellas Pharma US, Inc., do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Global Education Group, and Astellas Pharma US, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and …(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

This CME activity is provided by Integrity Continuing Education.

This activity is jointly provided by Global Education Group and Integrity Continuing Education.

Supported by an educational grant from Astellas Pharma US, Inc.

Continue to Pretest